---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-019045"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2026-03-18T23:59:59+00:00"
generated_at: "2026-05-15T09:53:49.295742+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics raises $60M PIPE, reports positive OV329 data, expands indications, and clears OV4071 for Phase 1

## Summary
- $60M PIPE: 19.15M shares at $2.01 and pre-funded warrants for 10.7M shares; closing expected March 19, 2026.
- OV329 7 mg cohort: no treatment-related adverse events; Phase 2 for focal onset seizures planned for Q2 2026.
- OV329 development expanded to tuberous sclerosis complex seizures (Q4 2026) and infantile spasms (2027).
- OV4071 (oral KCC2 activator) received HREC/TGA approval; Phase 1 in Australia starts Q2 2026.
- Cash $90.4M at Dec 31, 2025; net loss FY2025 $17.4M ($0.23/share); Series A warrants could add $53.9M.

## SEC filing metadata
- accession: 0001628280-26-019045
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2026-03-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828026019045/0001628280-26-019045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828026019045/ovid-20260318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-019045
- JSON: https://secwatch.observer/filing/0001628280-26-019045.json
- Plain text: https://secwatch.observer/filing/0001628280-26-019045.txt

## Key facts
- Material Agreements
  Ovid Therapeutics Inc. entered into Securities Purchase Agreement with the purchasers named therein valued at $60.0 million (effective 2026-03-17).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the purchasers named therein
  - Value: $60.0 million
  - Effective: 2026-03-17
  source text: On March 17, 2026, Ovid Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of 19,154,321 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $2.01 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000162828026019045/0001628280-26-019045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.